Internal Reference Number: FOI_7873
Date Request Received: 08/04/2024 00:00:00
Date Request Replied To: 10/04/2024 00:00:00
This response was sent via: By Email
Request Summary: Request on Asthma
Request Category: Private Individuals
| Question Number 1: How many patients have been treated (for any condition) in the last 4 months with: • Benralizumab • Dupilumab • Omalizumab • Reslizumab • Mepolizumab • Tezepelumab | |
| Answer To Question 1: • Benralizumab 0 patients • Dupilumab 23 patients • Omalizumab 26 patients • Reslizumab 0 patients • Mepolizumab 0 patients • Tezepelumab 0 patients | |
| Question Number 2: Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups: • Age 6-11 • Age 12-17 • Age 18 and above | |
| Answer To Question 2: All patients were 18 or over. 49 patients treated | |
| Question Number 3: . How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with: • Dupilumab • Omalizumab | |
| Answer To Question 3: Dupilumab 0 patients Omalizumab 12 patients | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
